ZIM Labs Q4 & FY26 EBITDA Down 16.4% YoY

ZIM Labs FY26 total operating income remained flat at ₹3,744 Mn, impacted by Mid-East war logistics and EU GMP audit deferral.
EBITDA declined 16.4% to ₹414 Mn with margins contracting 200 bps to 11.1% due to inflation and increased costs.
PAT fell 52% to ₹58 Mn, affected by lower EBITDA and higher depreciation/finance costs from project capex.
Board approved ₹35 Cr preferential issue of 47.64 lakh shares at ₹73.46 each to Florintree Trinex LLP.